Credit Suisse Ag Axsome Therapeutics, Inc. Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Credit Suisse Ag holds 43,721 shares of AXSM stock, worth $6.02 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,721

Previous 44,083 0.82%

Holding current value

$6.02 Million

Previous $3.51 Million 0.57%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$69.39 - $97.64 $25,119 - $35,345	-362 Reduced 0.82%	43,721 $3.49 Million
Q4 2023 Feb 08, 2024	SELL	$57.42 - $83.61 $758,518 - $1.1 Million	-13,210 Reduced 23.06%	44,083 $3.51 Million
Q3 2023 Nov 13, 2023	SELL	$69.25 - $82.21 $227,140 - $269,648	-3,280 Reduced 5.41%	57,293 $4 Million
Q2 2023 Aug 11, 2023	BUY	$58.41 - $90.35 $1.19 Million - $1.84 Million	20,350 Added 50.59%	60,573 $4.35 Million
Q1 2023 May 10, 2023	SELL	$58.39 - $75.0 $287,220 - $368,925	-4,919 Reduced 10.9%	40,223 $2.48 Million
Q4 2022 Feb 13, 2023	SELL	$39.94 - $79.72 $657,971 - $1.31 Million	-16,474 Reduced 26.74%	45,142 $3.48 Million
Q3 2022 Nov 10, 2022	BUY	$36.06 - $69.85 $916,392 - $1.78 Million	25,413 Added 70.2%	61,616 $2.75 Million
Q2 2022 Aug 12, 2022	SELL	$21.74 - $46.75 $216,443 - $465,443	-9,956 Reduced 21.57%	36,203 $1.39 Million
Q1 2022 May 16, 2022	SELL	$23.7 - $41.39 $1.8 Million - $3.15 Million	-76,084 Reduced 62.24%	46,159 $1.91 Million
Q4 2021 Feb 14, 2022	BUY	$30.7 - $43.36 $726,392 - $1.03 Million	23,661 Added 24.0%	122,243 $4.62 Million
Q3 2021 Nov 12, 2021	BUY	$19.91 - $68.26 $1.29 Million - $4.43 Million	64,955 Added 193.16%	98,582 $3.25 Million
Q2 2021 Aug 16, 2021	SELL	$50.63 - $73.5 $263,579 - $382,641	-5,206 Reduced 13.41%	33,627 $2.27 Million
Q1 2021 May 14, 2021	BUY	$55.91 - $81.44 $137,706 - $200,586	2,463 Added 6.77%	38,833 $2.2 Million
Q4 2020 Feb 12, 2021	BUY	$66.31 - $86.52 $922,902 - $1.2 Million	13,918 Added 61.99%	36,370 $2.96 Million
Q3 2020 Nov 13, 2020	SELL	$68.34 - $85.84 $320,924 - $403,104	-4,696 Reduced 17.3%	22,452 $1.6 Million
Q2 2020 Aug 12, 2020	BUY	$49.87 - $98.69 $566,922 - $1.12 Million	11,368 Added 72.04%	27,148 $2.23 Million
Q1 2020 May 13, 2020	SELL	$41.2 - $101.31 $1.02 Million - $2.51 Million	-24,787 Reduced 61.1%	15,780 $928,000
Q4 2019 Feb 12, 2020	BUY	$16.71 - $106.24 $371,713 - $2.36 Million	22,245 Added 121.41%	40,567 $4.19 Million
Q3 2019 Nov 12, 2019	SELL	$20.24 - $29.16 $79,806 - $114,977	-3,943 Reduced 17.71%	18,322 $371,000
Q2 2019 Aug 14, 2019	BUY	$13.46 - $25.75 $299,686 - $573,323	22,265 New	22,265 $573,000
Q3 2017 Nov 14, 2017	SELL	$4.65 - $6.1 $78,831 - $103,413	-16,953 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	16,953	16,953 $93,000

Others Institutions Holding AXSM

# of Institutions

351

Shares Held

36.3M

Call Options Held

1.77M

Put Options Held

1.16M

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $5.91B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account